? The FDA is already reviewing the issue ? an advisory panel convened in September ? but it hasn t taken action yet and declined to comment on the bill . Nate Brown of Akin Gump , who previously served in FDA s Office of Chief Counsel , said that even in cases concerning public health issues it would be quite unusual for Congress to legislate specific treatment of a particular type of device . Bayer , meanwhile , defended the device ' s safety in a statement and said " it is critical that the scientific , data driven process already in place at FDA continues to guide the path forward . "
